Elicio Therapeutics Inc
ELTX8.320USD
+0.710+9.33%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
143.59MCap. mercado
PérdidaP/E TTM
Más Datos de Elicio Therapeutics Inc Compañía
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Información de Elicio Therapeutics Inc
Símbolo de cotizaciónELTX
Nombre de la empresaElicio Therapeutics Inc
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoConnelly (Robert)
Número de empleados32
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
Dirección451 D Street, 5Th Floor
CiudadBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02459
Teléfono18572090050
Sitio Webhttps://elicio.com/
Símbolo de cotizaciónELTX
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoConnelly (Robert)
Ejecutivos de Elicio Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-10311.00%
Dr. Preetam Shah, Ph.D.
Dr. Preetam Shah, Ph.D.
Principal Financial Officer, Principal Accounting Officer, Chief Strategy Officer
Principal Financial Officer, Principal Accounting Officer, Chief Strategy Officer
24.00K
+24000.00%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
+12725.00%
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
743.00
+362.00%
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Connelly
Mr. Robert (Bob) Connelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Carol Ashe
Ms. Carol Ashe
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-10311.00%
Dr. Preetam Shah, Ph.D.
Dr. Preetam Shah, Ph.D.
Principal Financial Officer, Principal Accounting Officer, Chief Strategy Officer
Principal Financial Officer, Principal Accounting Officer, Chief Strategy Officer
24.00K
+24000.00%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
+12725.00%
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
743.00
+362.00%
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: lun., 2 de feb
Actualizado: lun., 2 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
GKCC, LLC
30.97%
Knoll Capital Management, LLC
3.61%
The Vanguard Group, Inc.
2.84%
Actyus Private Equity SGIIC, S.A.
1.54%
Venkatesan (Jay R)
0.97%
Otro
60.07%
Accionistas
Accionistas
Proporción
GKCC, LLC
30.97%
Knoll Capital Management, LLC
3.61%
The Vanguard Group, Inc.
2.84%
Actyus Private Equity SGIIC, S.A.
1.54%
Venkatesan (Jay R)
0.97%
Otro
60.07%
Tipos de accionistas
Accionistas
Proporción
Corporation
32.50%
Hedge Fund
4.86%
Investment Advisor
4.84%
Holding Company
2.75%
Individual Investor
2.33%
Investment Advisor/Hedge Fund
2.25%
Private Equity
0.31%
Research Firm
0.18%
Otro
49.97%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
58
2.05M
11.00%
--
2025Q3
59
2.05M
11.96%
+477.65K
2025Q2
52
1.58M
11.53%
-116.12K
2025Q1
59
1.67M
8.91%
+250.74K
2024Q4
54
504.27K
8.35%
-37.38K
2024Q3
58
541.64K
9.80%
-115.54K
2024Q2
70
657.30K
8.80%
+242.22K
2024Q1
96
415.08K
8.40%
-443.93K
2023Q4
102
540.87K
10.06%
+911.00
2023Q3
115
547.56K
11.25%
+45.29K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
GKCC, LLC
5.42M
30.97%
--
--
Jun 03, 2025
Knoll Capital Management, LLC
630.91K
3.61%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
473.86K
2.71%
+19.24K
+4.23%
Sep 30, 2025
Actyus Private Equity SGIIC, S.A.
268.56K
1.54%
-587.82K
-68.64%
Sep 30, 2025
Venkatesan (Jay R)
170.22K
0.97%
-10.31K
-5.71%
Mar 24, 2025
Balyasny Asset Management LP
148.08K
0.85%
+148.08K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
129.69K
0.74%
+8.86K
+7.33%
Sep 30, 2025
Connelly Robert
46.97K
0.27%
--
--
Mar 24, 2025
Susquehanna International Group, LLP
120.21K
0.69%
+103.18K
+606.14%
Sep 30, 2025
Marshall Wace LLP
86.53K
0.49%
+86.53K
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
iShares Micro-Cap ETF
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
